Latest Interest Rates News

Quickstep Holdings reports a 21% revenue decline but a 44% EBITDA increase in Q2 FY25, driven by restructuring and strategic progress with Defence contracts.

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.

Entyr Limited has ramped up tyre receivals and processing volumes in the December quarter, alongside securing new supply and offtake agreements as it prepares for ASX reinstatement. The company’s ongoing plant upgrades and strategic partnerships signal a potential turnaround in its operational and financial trajectory.

ReNu Energy has raised $500,000 through loan notes that may convert into shares and options pending shareholder approval, aiming to bolster working capital.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

ADX Energy Ltd's December quarter cash flow report reveals a $1.18 million net cash decrease from operations, with $9.08 million cash on hand and ongoing financing adjustments.

Associate Global Partners Limited (AGP) reported its strongest quarterly net inflows since 2017, driving funds under management to $1.72 billion amid successful capital raising and robust investment performance.

Hudson Investment Group signals potential corporate restructure as it explores sale and joint venture options for key Queensland and NSW properties.

AVADA Group Limited reports a positive cash flow for Q4 2024, supported by increased collections and operational consolidation, even as government funding shifts delay project starts.

AGP Investment Management Limited has announced a $0.009 per unit distribution for the Switzer Dividend Growth Fund for January 2025, fully franked and supported by an active Distribution Reinvestment Plan.

Develop Global Limited reported a robust increase in cash reserves for the December 2024 quarter, driven by significant financing inflows despite ongoing operational and investing outflows.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.